UPDATE: Deutsche Bank Raises PT to $29 on Team Health on Revenue Visibility
Deutsche Bank reiterated its Buy rating on Team Health (NYSE: TMH) and raised its price target from $26 to $29.
Deutsche Bank noted, "We expect another strong quarter, driven by top-line growth that should remain balanced b/w organic (same-contract), new contract sales and contributions from M&A. In light of strong rev growth visibility, we are raising our PT to $29 (from $26) and now put the fwd EV/EBITDA at the upper end of the group's historical 8x-9x range."
Team Health closed at $26.94 on Monday.
Latest Ratings for TMH
|Sep 2014||Stifel Nicolaus||Maintains||Buy|
|Sep 2014||Deutsche Bank||Maintains||Hold|
|Aug 2014||Deutsche Bank||Upgrades||Buy||Hold|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.